Cancer trials · JAMA Network Open · 2022
Paper: trials had too few Asian or Pacific Islander patients. Its own count shows the opposite.
Share Asian or Pacific Islander, 2000 to 2018: trial patients vs new cancer cases
The paper says
Of 8,309 patients in early US cancer-drug trials (2000–2018), 4.5% were Asian or Pacific Islander. The paper says 5.9% of new cancer cases in a North American registry were, so trials fell short by 1.5 percentage points, a gap chance alone would rarely produce.
Its own data show
In that same sentence the paper prints the registry’s count beside the 5.9%: 145,568 of 4,891,486 cases. That is 3.0%. So trials, at 4.5%, had a larger share, by 1.5 points: the same gap, the other way round. The count is exactly the paper’s 2000–2011 (2.7%) and 2012–2018 (3.4%) counts added together.
Pool two groups and the combined share always lands between the two: a 2.7% group and a 3.4% group cannot make 5.9%. So 5.9% cannot be right, yet the paper’s conclusions still list too few Asian or Pacific Islander patients overall. Its main finding, too few Black patients, does not depend on this error.